Page 230 - Drug Class Review
P. 230
Page 145 of 205
Drug Effectiveness Review Project
Country: Multinational (Canada, Finland, France, Germany, Norway, Sweden, Netherlands, UK)
placebo N/A 6 months 215
galantamine 32 mg/d 6 months 218 Probable AD according to the NINCDS; MMSE score of 11-24; ADAS-Cog score > 12; FAST ≤ 6 at Had no responsible caregiver; neurogenerative disorder; multi-infarct dementia or clinically active CVD; cardiovascular disease thought to prevent study completion; clinically important cerebrovascular, psychiatric, hepatic, renal, pulmonary, metabolic, or endocrine conditions or urinary outflow obstruction; active peptic ulcer; any history of epilepsy or serious drug or alcohol misuse; history of treatment with Most concomita
Drugs Authors: Wilcock et al. 53 Janssen Research Foundation To evaluate the efficacy and safety of GAL in the treatment of AD Setting: Multi-center (86) Sample size: 653 randomized (525 completed) galantamine 24 mg/d 6 months 220
Alzheimer Year: 2000 Study design: RCT baseline ChE inhibitor cognitive evaluation
Final Report Update 1 Efficacy/Effectiveness STUDY: FUNDING: RESEARCH OBJECTIVE: DESIGN: INTERVENTION: Dose: Duration: Sample size: INCLUSION: EXCLUSION: OTHER MEDICATIONS/ INTERVENTIONS ALLOWED: Alzheimer's Drugs
